Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,624 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: dATS Clear all
Completed Phase 1 Interventional

Cognitive Behavior Therapy for Treating Anxiety in People With Dementia

NCT00596284
View directory record Official record
Conditions
Anxiety Disorders, Dementia
Interventions
Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD), Enhanced Usual Care (EUC)
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 28, 2026, 4:47 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)

NCT03702816
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Inflammation
Interventions
GE180 PET Scan
Drug
Lead sponsor
Aaron Ritter, MD
Other
Eligibility
55 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 28, 2026, 4:47 AM EDT
Recruiting Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

NCT06808984
View directory record Official record
Conditions
Agitation, Alzheimer Disease
Interventions
BMS-986368, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
55 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
60
States / cities
Homewood, Alabama • Huntsville, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 4:47 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Health Evaluation in African Americans Using RAS Therapy

NCT02471833
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Telmisartan 20mg, Telmisartan 40mg, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
30 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 28, 2026, 4:47 AM EDT
Recruiting Phase 2 Interventional

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

NCT06847321
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Disease Due to P. Gingivalis
Interventions
LHP588, Placebo Drug
Drug
Lead sponsor
Lighthouse Pharmaceuticals, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Murrieta, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 28, 2026, 4:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease

NCT00901498
View directory record Official record
Conditions
Alzheimer's Disease, Healthy
Interventions
BMS-708163
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 7, 2011 · Synced Oct 28, 2026, 4:47 AM EDT
Terminated Phase 3 Interventional

The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease

NCT00006187
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Investigational drug
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
34
States / cities
Peoria, Arizona • Beverly Hills, California • Los Alamitos, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 28, 2026, 4:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comprehensive Support for Alzheimer's Disease Caregivers

NCT00362284
View directory record Official record
Conditions
Caregivers, Stress, Depression
Interventions
NYUCI-AC
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 28, 2026, 4:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

REVEAL III: Risk Evaluation and Education for Alzheimer's Disease

NCT00462917
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Pleiotropic info, in-person disclosure, AD-only info, in-person disclosure, Pleiotropic info, phone disclosure, AD-only info, phone disclosure
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 28, 2026, 4:47 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

NCT06999434
View directory record Official record
Conditions
Demyelinating Disorders, MCI, Alzheimer's Disease (AD), MS (Multiple Sclerosis), SCI - Spinal Cord Injury, Spinal Radiculopathy
Interventions
[ 18F]3F4AP, [18F]MK6240, [11C]PIB
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 28, 2026, 4:47 AM EDT
Recruiting Phase 2 Interventional

Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)

NCT05565833
View directory record Official record
Conditions
Insomnia, Cognitive Dysfunction, Mild Cognitive Impairment, Sleep Initiation and Maintenance Disorders, Sleep Disorders, Intrinsic, Dyssomnias, Sleep Wake Disorders, Nervous System Diseases, Alzheimer Disease
Interventions
SHUTi OASIS, Patient Education
Behavioral · Other
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 28, 2026, 4:47 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

NCT02972658
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Lanabecestat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 28, 2026, 4:47 AM EDT
Recruiting Phase 2 Interventional

Open-Label Extension Protocol to SNK01-AD01 Study

NCT07228078
View directory record Official record
Conditions
Alzheimer Disease
Interventions
SNK01
Biological
Lead sponsor
NKGen Biotech, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 28, 2026, 4:47 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Rocky Mountain Alzheimer's Disease Center Longitudinal Biomarker and Clinical Phenotyping Study

NCT02612376
View directory record Official record
Conditions
Alzheimer Disease, Down Syndrome, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 28, 2026, 4:47 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198

NCT02226835
View directory record Official record
Conditions
Age-Related Macular Degeneration, Alzheiner's Disease, AMD
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
45 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 28, 2026, 4:47 AM EDT
Not listed No phase listed Observational

Evidence Amyloid Scan EEG Study

NCT03644043
View directory record Official record
Conditions
Alzheimer Disease, Dementia Frontal, Mild Cognitive Impairment
Interventions
EEG scan
Device
Lead sponsor
Metabolic Therapy Inc.
Other
Eligibility
60 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 28, 2026, 4:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Finger Prick Collection Method for Measuring Alzheimer's Disease Blood Biomarkers

NCT07187921
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
Banner Health
Other
Eligibility
50 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 28, 2026, 4:47 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Brain NAD in Alzheimer's Disease

NCT07127510
View directory record Official record
Conditions
Alzheimer Disease (AD)
Interventions
Not listed
Lead sponsor
Florida Atlantic University
Other
Eligibility
65 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 28, 2026, 4:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Retain Your Brain Health Study (RetainYourBrain.com)

NCT06027320
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Healthy Participants, Brain Health
Interventions
Brain Health Education, Alzheimer Disease Education
Behavioral
Lead sponsor
Retain Health, Inc
Other
Eligibility
53 Years to 105 Years
Enrollment
992 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 28, 2026, 4:47 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

NCT04241068
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aducanumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
104
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 28, 2026, 4:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

NCT02392468
View directory record Official record
Conditions
Schizophrenia, Alzheimer Disease
Interventions
Placebo matching BI 409306 25 mg, Placebo matching BI 409306 50 mg, BI 409306 25 mg, BI 409306 50 mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
3
States / cities
La Jolla, California • Eatontown, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 28, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

Effects of an Anti-Inflammatory Drug in Alzheimer's Disease

NCT00013650
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Cyclophosphamate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
50 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 4:47 AM EDT
Not listed Phase 2Phase 3 Interventional

Thalidomide for Patients With Mild to Moderate Alzheimer's Disease

NCT01094340
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Thalidomide
Drug
Lead sponsor
Banner Health
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Sun City, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 28, 2026, 4:47 AM EDT
Completed Phase 1 Interventional

CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00087789
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CERE-110: Adeno-Associated Virus Delivery of NGF
Genetic
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
San Diego, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 28, 2026, 4:47 AM EDT